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INTRODUCTION
Uniparental disomy (UPD) occurs when the two copies of a (part of a) chromosome are derived from one parent only. If this chromosome contains imprinted gene(s), this can result in human disease due to loss of gene function and can lead to congenital anomalies, intellectual disability, and other health problems. 1 If both copies of (a part of) a chromosome are derived from the father, this is called paternal UPD (patUPD). Five syndromes are associated with patUPD: transient neonatal diabetes mellitus (patUDD6), Beckwith-Wiedemann syndrome (BWS) (patUPD11), Kagami-Ogata Abbreviations: BAF, B-allele frequency; BWS, Beckwith-Wiedemann syndrome; GOM, gain of methylation; IC, imprinting center; LOM, loss of methylation; MGWpatUPD, mosaic genome-wide paternal uniparental disomy; MS-MLPA, methylation-specific multiplex ligation-dependent probe amplification; SNP, single-nucleotide polymorphism; UPD, uniparental disomy.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. syndrome (patUPD14), Angelman syndrome (patUPD15), and patUPD20. 2 PatUPD of the whole genome is lethal in utero, as it presents as hydatidiform mole. 3 If UPD of the whole genome is present in a mosaic state, it can be compatible with life. In 1995, mosaic genome-wide paternal UPD (MGWpatUPD) was first described in a patient with BWS and a Wilms tumor. 4 Since then, 17 additional cases have been described (Table 1) . 3, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Here, we describe a female with multiple benign and malignant tumors, occurring at various ages, in whom eventually Table 2 patient with earlier reported individuals and offer clues for recognition.
CASE DESCRIPTION
The index case was the third child of healthy, nonconsanguineous Dutch parents (aged 32 and 34 years). Weight at birth after 35 weeks of gestation was 2520 g (P50-75). The placenta was remarkably large, weighing 1890 g (>P98). Immediately after birth and later during life, she developed multiple benign tumors (please see Table 2 for an overview of all tumors). At one year of age, a body asymmetry became apparent, with the left side being larger. General health was good; growth and cognition were undisturbed.
She had two children, one of whom was born with tetralogy of Fallot without other abnormalities. When she was 37 years, a malignant adrenocortical tumor from the right adrenal gland was surgically removed. At 39 years, she developed a yolk sac tumor in the sacral region, which could only partly be removed due to massive local invasion. Curative therapy was not possible and she died within a few months' time.
Tumor material and peripheral blood were examined using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) and single-nucleotide polymorphism (SNP) array (please see Supporting Information for additional information).
RESULTS
In 1997, at 19 years of age, diagnostic testing for BWS was performed Figure S3b ). Both strongly suggest a high level (±95%)
MGWpatUPD in the tumor. SNP array analysis of the yolk sac tumor material from the sacral region showed a similar aberrant BAF profile, and many gains and losses of (large parts of) chromosomes (Supporting Information Figure S3c ).
Results were discussed with the patient and her family, explaining that this de novo genomic imbalance was most likely the cause of her asymmetry and recurrent tumors, and that this implies no increased cancer risks for her offspring and other relatives.
DISCUSSION
The occurrence of several tumors and asymmetrical body growth as present in the index case can be associated with MGWpatUPD. The initial methylation studies, 20 years ago, could not establish this diagnosis, as the level of mosaicism for the UPD was below the detection threshold of the methylation test. Sensitivity of diagnostic genetic tests has improved since then. Still, even today sensitivity of testing is not complete, which should be taken into account in evaluating results of such testing in the light of a suspected clinical diagnosis.
In patients with MGWpatUPD, the BWS phenotype is predominant;
in individuals with a BWS phenotype, an MGWpatUPD might remain unrecognized if methylation analyses are restricted to a single UPD region, e.g., 11p15. 18, 19 To check for this, methylation tests at various loci should be undertaken if methylation testing for 11p15 is suggestive for patUPD (loss LIT1 and gain H19). Due to the mosaicism, aberrations may not be detectable in DNA derived from leucocytes, so other tissues may need to be studied to prove MGWpatUPD.
The presented patient is the oldest reported individual with an MGWpatUPD; the other patients range in age from 1 month to 30 years (Table 1) . [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Obviously, all patients are female, as an androgenetic lineage (containing two Y chromosomes and no X chromosome)
is not viable. 19 Likely, tissue-specific effects of imprinted genes allow low-level mosaic paternal UPD11 to cause signs and symptoms, and inhibits symptoms of the other low-level mosaic paternal UPDs. 13 Fifteen of 19 patients (79%) previously reported with MGWpatUPD developed tumors, and 12 of them developed more than a single tumor ( Table 2 ). The four patients in whom no tumor was described were < 13. 
